Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion Collaborates with University of Leicester on Icovamenib-Semaglutide Obesity Study

Biomea Fusion has announced a research collaboration with the University of Leicester to evaluate its investigational menin inhibitor, icovamenib, in combination with semaglutide for obesity. This new arm within the OPAL platform study will assess the combination's potential impact on physical function, body weight, body composition, muscle health, and metabolic outcomes. The randomized, double-blinded study will compare icovamenib (100 mg, QD for 12 weeks) plus low-dose semaglutide (for 24 weeks) against low-dose semaglutide alone (for 24 weeks) in overweight or obese individuals without type 2 diabetes. Enrollment is set to begin in the third quarter, with primary outcome assessment at Week 24. Preclinical data suggest synergistic effects, including enhanced fat loss while preserving lean mass.

• The collaborative study is an experimental arm within the ongoing OPAL platform trial, designed as a randomized, double-blinded study. It will evaluate icovamenib (100 mg, QD for 12 weeks) in combination with low-dose semaglutide (for 24 weeks) versus low-dose semaglutide alone (for 24 weeks) in overweight or obese individuals without type 2 diabetes. Enrollment is anticipated to commence in the third quarter, with the primary outcome assessment scheduled for Week 24.
• The study aims to address a critical question in obesity treatment: how to optimize weight loss while preserving lean mass and functional health. By combining icovamenib with semaglutide, researchers hope to enhance the body weight-lowering effects of GLP-1 therapy and provide benefits beyond weight reduction, including improved physical function, muscle mass, and overall metabolic health, based on encouraging preclinical synergistic effects.
• Preclinical evidence supports the combination, showing that icovamenib combined with low-dose semaglutide enhanced weight reduction driven by fat loss, preserved lean mass, and improved glycemic control in a type 2 diabetic rat model. Biomea Fusion will also present late-breaking preclinical findings at the 86th American Diabetes Association (ADA) Scientific Sessions, detailing mechanisms through which icovamenib may support metabolic health, reinforcing its potential for obesity and diabetes.

Beyond Weight Loss: Addressing Unmet Needs in Obesity Management

Recent literature reveals several critical unmet needs in obesity management, with particular focus on populations with comorbidities and addressing significant treatment barriers. The evidence demonstrates that 94% of people with obesity have at least one comorbidity, highlighting the complexity of clinical management beyond simple weight reduction.

• Patients with BMI ≥27 kg/m² and comorbidities represent a primary target population, with consistent recommendations across multiple healthcare systems for drug therapy when lifestyle interventions prove insufficient

• Access barriers significantly limit treatment utilization, with 38% of patients reporting insurance restrictions, 37% citing concerns about side effects, and 31% identifying cost as major obstacles to obesity medication initiation

• Treatment duration expectations are suboptimal, as 56% of patients expect limited medication duration (20% anticipating less than one year, 28% less than two years), with duration expectations varying based on out-of-pocket costs

• Genetic obesity populations require specialized approaches, particularly patients with melanocortin-4-receptor (MC4R) deficiency—the most common monogenic cause of obesity—where 27% of UK patients seeking severe obesity treatment carried relevant mutations

• College students emerge as an underserved population, with obesity prevalence of 21% in males and 9.2% in females, requiring strategic multidisciplinary interventions during this critical period for establishing healthy behaviors

• Heart failure patients with obesity face dual management challenges, representing 30-40% of heart failure cases with bidirectional pathophysiological relationships requiring integrated treatment strategies

• Communication gaps exist in clinical practice, where healthcare provider discussions frequently address side effects and administration but lack consistency in treatment duration planning and lifestyle integration strategies

• Regional disparities require population-specific adaptations, such as adjusted BMI thresholds for South Asian populations (>25 kg/m²) and addressing healthcare infrastructure limitations in developing regions

Designing the OPAL Study for Icovamenib and Semaglutide

Recent studies investigating obesity have employed diverse methodological approaches ranging from large-scale observational cohorts to randomized controlled trials with multi-omics profiling. These trials have evaluated both traditional weight loss metrics and novel biomarkers across varied patient populations and intervention types.

Icovamenib and Semaglutide: A Novel Combination Approach

Recent clinical trials are investigating several innovative combination therapy approaches for obesity treatment, with particular focus on next-generation incretin-based therapies and multi-target agonists. The most advanced developments involve tirzepatide combination strategies and novel dual/triple receptor agonists that simultaneously target multiple metabolic pathways to enhance weight loss efficacy beyond what single-agent therapies can achieve.

Tirzepatide combination approaches have shown promising results in recent SURMOUNT trial analyses, demonstrating significant weight reduction even when used concomitantly with weight-inducing medications. Post hoc analyses from SURMOUNT-1, -3, and -4 trials revealed that approximately 17-20% of participants were using weight-inducing medications, yet still achieved substantial weight loss ranging from -13.3% to -21.3% with tirzepatide 5-15mg in SURMOUNT-1, -26.1% in SURMOUNT-3, and -18.6% in SURMOUNT-4 compared to placebo. Additionally, a novel phase II trial (ChiCTR2500102009) is investigating tirzepatide as adjunctive therapy to standard fertility-sparing treatment in obese patients with endometrial cancer, targeting both weight reduction and reversal of endometrial lesions through combination therapy.

Multi-receptor agonist approaches represent the next frontier in obesity pharmacotherapy, with several GCGR-based combination agents demonstrating substantial efficacy. Retatrutide, the most advanced triple agonist targeting GLP-1, GIP, and glucagon receptors, achieved up to 24.2% mean weight loss after 48 weeks while improving multiple cardiometabolic parameters including blood pressure, lipids, and hepatic steatosis (82% reduction). Survodutide, a dual glucagon receptor and GLP-1 receptor agonist, is being evaluated in the multinational SYNCHRONIZE-1 phase III trial, investigating once-weekly subcutaneous injections (3.6 or 6.0 mg) for 76 weeks in adults with obesity without type 2 diabetes, building on promising phase II results that demonstrated significant weight loss in this population.

Menin Inhibitors: A Strategic Pivot to the Obesity Market

The pharmaceutical landscape is witnessing an intriguing strategic pivot as Biomea Fusion announces a research collaboration to investigate its menin inhibitor, icovamenib, for obesity. This move is particularly noteworthy given that menin inhibitors have predominantly been developed and recently approved for acute leukemias, specifically KMT2A-rearranged and NPM1-mutated subtypes, where they address a significant unmet need in high-risk patient populations. The exploration of icovamenib in a metabolic indication represents a substantial expansion of the drug class's therapeutic potential and a bold diversification for the company.

The decision to combine icovamenib with semaglutide, a widely used GLP-1 agonist, suggests a strategic intent to carve out a differentiated niche within the rapidly growing and competitive obesity market. Preclinical data hinting at synergistic effects, particularly enhanced fat loss while preserving lean mass, could be a significant advantage. Current weight loss therapies, while effective, often lead to some degree of muscle loss, making a therapy that mitigates this a compelling proposition. The upcoming randomized, double-blinded study will be crucial in determining if these preclinical observations translate into meaningful clinical benefits across physical function, body composition, and metabolic outcomes in overweight or obese individuals.

However, this novel application is not without its considerations. Menin inhibitors, as a class, have demonstrated specific safety profiles in oncology settings, including the potential for differentiation syndrome and QTc prolongation. While these may not directly translate to a non-oncology population, careful monitoring will be essential. Furthermore, the emergence of acquired resistance mechanisms, such as MEN1 mutations, has been observed in leukemia trials, raising questions about long-term efficacy if similar adaptive pathways exist in metabolic contexts. The success of this venture hinges on demonstrating a favorable risk-benefit profile and clear clinical differentiation, potentially opening a new chapter for menin inhibitors beyond their established roles.